CTLA4 and non-small cell lung carcinoma: In recent years, immune checkpoint inhibitors (ICIs) blocking programmed cell death‐1 (PD‐1) and cytotoxic T‐lymphocyte‐associated antigen‐4 (CTLA‐4) have emerged as new therapeutic options in metastatic NSCLC.